This activity is supported by educational grants from commercial interests. Complete information will be provided to participants prior to the activity. Educational credit will be available to attendees. Complete details about accreditation and credit designation are available online.
Medical professionals who treat patients with allergic and/or immunological conditions:
At the conclusion of this activity, participants should be able to:
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 28.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239 and this activity has been designated for up to 28.75 Continuing Education contact hours
This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 28.75 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
ACAAI will not be designating any 2023 Annual Meeting sessions for MOC Part II Self-Assessment Credit. However, you’ll find other opportunities to earn MOC Part II Self-Assessment credit on the College Learning Connection (education.acaai.org).
IMPORTANT: ABAI’s MOC program requires Diplomates to obtain a minimum of 25 CME credits in allergy and immunology each year. CME credits for the Annual Meeting can be applied to this requirement.
Back to Top